Recombinant Human Antibody (PGT151) is capable of binding to HIV-1 env, expressed in HEK 293 cells. Expressed as the combination of a heavy chain (HC) containing VH from anti-HIV-1 env mAb and CH1-3 region of human IgG1 and a light chain (LC) encoding VL from anti-HIV-1 env mAb and CL of human light chain. Exists as a disulfide linked dimer of the HC and LC hetero-dimer under non-reducing condition. The PGT151 epitope is comprised of residues and glycans at the interface of gp41 and gp120 within a single protomer and glycans from both subunits of a second protomer and represents a neutralizing epitope that is dependent on both gp120 and gp41.
Figure 1 PGT151–158 neutralization of an indicator panel of 5 pseudoviruses
Serial dilutions of antibody were preincubated with pseudovirus for 1 hour and then added to TZM-bl cells. Three days post-infection luciferase values were measured and % neutralization was calculated.
Falkowska, E., Le, K. M., Ramos, A., Doores, K. J., Lee, J. H., Blattner, C.,... & Mcbride, R. (2014). Broadly neutralizing HIV antibodies define a glycan-dependent epitope on the prefusion conformation of gp41 on cleaved envelope trimers.Immunity, 40(5), 657-668.
Figure 2 PGT151 and PGT152 binding to different forms of Env
(A) PGT151 and PGT152 do not bind to JR-FL gp120 monomer as measured by ELISA. (B) PGT151 binds to native, cleaved (cl) but not to uncleaved (uncl) JR-FL E168K trimers expressed on the surface of 293T cells as measured by flow cytometry, and (C) PGT151 and PGT152 bind to cleaved soluble BG505 SOSIP.664 gp140 trimers but not to the corresponding uncleaved gp140 trimers as measured by ELISA.
Falkowska, E., Le, K. M., Ramos, A., Doores, K. J., Lee, J. H., Blattner, C.,... & Mcbride, R. (2014). Broadly neutralizing HIV antibodies define a glycan-dependent epitope on the prefusion conformation of gp41 on cleaved envelope trimers.Immunity, 40(5), 657-668.
Figure 3 PGT151-PGT158 bind complex carbohydrates
(A) PGT151 and PGT152 neutralization of JR-CSF pseudovirus generated (i) in the presence of the glycosidase inhibitor swainsonine, which prevents the formation of complex glycans by inhibiting the trimming of mannose residues from the Man-α6 arm of the GlcNAcMan5GlcNAc2 structure or (ii) in 293S cells (GNT1−/− cells), a cell line that is deficient in N-acetylglucosaminyltransferase I and is unable to add a GlcNAc residue to the Man5GlcNAc2 structure to permit processing to complex glycans. Neutralization of JR-SCF pseudovirus by 2G12 is not affected by either (i) or (ii) since it binds exclusively to high-mannose glycans on the glycan shield of Env. (B) Glycan microarray analysis reveals PGT151-PGT158 preferentially bind tetraantennary complex carbohydrates and PGT151 additionally binds a triantennary glycan as detected on the Wong glycan array. (C) Glycan microarray analysis using the CFG microarray additionally reveals that all PGT151 family MAbs except PGT153 preferentially bind triantennary complex carbohydrates; and (D) PGT151 and PGT152 bind a tetrantennary complex carbohydrate on the neoglycolipid microarray. The symbols for common monosaccharides are as follows: purple diamonds represent sialic acid, yellow circles represent galactose, red triangles represent fucose, blue squares represent N-acetyl glucosamine and green circles represent mannose.
Falkowska, E., Le, K. M., Ramos, A., Doores, K. J., Lee, J. H., Blattner, C.,... & Mcbride, R. (2014). Broadly neutralizing HIV antibodies define a glycan-dependent epitope on the prefusion conformation of gp41 on cleaved envelope trimers.Immunity, 40(5), 657-668.
Figure 4 PGT151 neutralization of viruses containing N611A, N637A, E647A single and double alanine substitutions
Serial dilutions of antibody (A) PGT151 and (B) PGV04, used as a control, were preincubated with pseudovirus for 1 hour and then added to TZM-bl cells. Three days post-infection luciferase values were measured and % neutralization was calculated.
Falkowska, E., Le, K. M., Ramos, A., Doores, K. J., Lee, J. H., Blattner, C.,... & Mcbride, R. (2014). Broadly neutralizing HIV antibodies define a glycan-dependent epitope on the prefusion conformation of gp41 on cleaved envelope trimers.Immunity, 40(5), 657-668.
Figure 5 ADCC by PGT151 and PGT152
(A) PGT151 and (B) PGT152 were titered for ADCC activity against target cells infected with HIV-1 NL4–3, YU2, JR-CSF and SIVmac239, and using an NK cell line (KHYG-1) expressing CD16 as the effector cell. The killing of virus-infected cells by ADCC is indicated by a loss of relative light units (RLU). SIVmac239 is used as a negative control and HIVIG is used as a positive control.
Falkowska, E., Le, K. M., Ramos, A., Doores, K. J., Lee, J. H., Blattner, C.,... & Mcbride, R. (2014). Broadly neutralizing HIV antibodies define a glycan-dependent epitope on the prefusion conformation of gp41 on cleaved envelope trimers.Immunity, 40(5), 657-668.
Figure 6 B) JRFL gp140 NFLP with 1-3x G4S linkers were screened by IP with selected mAbs, Trimer-specific bNAbs are highlighted in red. (C). IP of BG505 gp140 NFL2P from crude cell supernatant by selected mAbs (trimer-specific mAbs highlighted in red). Note that the IP band intensity for non-NAb F105 is relatively light compared to those of the bNAbs, suggesting the majority of expressed protein is well-ordered trimers.
Sharma, S. K., de Val, N., Bale, S., Guenaga, J., Tran, K., Feng, Y.,... & Wyatt, R. T. (2015). Cleavage-independent HIV-1 Env trimers engineered as soluble native spike mimetics for vaccine design. Cell reports, 11(4), 539-550.
Yamamoto, Mizuki, et al. "Cell-cell and virus-cell fusion assay-based analyses of alanine insertion mutants in the distal α9 portion of the JRFL gp41 subunit from HIV-1." Journal of Biological Chemistry 294.14 (2019): 5677-5687. https://doi.org/10.1074/jbc.RA118.004579
This research investigates alanine insertion mutations in the distal portion of the α9 helix in the gp41 subunit of HIV-1 envelope protein (Env). The study focuses on six alanine insertion mutants in the R5-tropic JRFL Env, specifically targeting positions 641-646 where several glutamine residues are conserved. The researchers found that the 644A mutant showed the most severe defect in syncytia formation, with decreased fusion pore activity observed in all mutants except 641A. Through sequence analysis and substitution experiments, they demonstrated that the glutamine residue at position 644, which forms complex hydrogen-bond networks with other polar residues on the six-helix bundle surface, is critical for cell-cell fusion. Additionally, the team developed a split NanoLuc reporter-based assay specifically for the virus-cell membrane fusion step, revealing that even syncytia-competent mutants failed to display NanoLuc activities, suggesting differences between cell-cell and virus-cell fusion mechanisms.
Creative Biolabs provided the anti-HIV-1 Env neutralizing antibody (clone PGT151), which was used to validate the specificity of their newly developed R-BiT (Vpr-HiBiT) assay for membrane fusion. This antibody, along with other inhibitors, helped confirm that the novel assay could faithfully monitor the membrane fusion step of viral infection independent of downstream replication steps such as reverse transcription and integration. The use of PGT151 was instrumental in demonstrating the technical reliability of their fusion-specific assay, enabling the researchers to make more accurate distinctions between the fusion capabilities of wild-type and mutant Env proteins.
This is a product of Creative Biolabs' Hi-Affi™ recombinant antibody portfolio, which has several benefits including:
• Increased sensitivity
• Confirmed specificity
• High repeatability
• Excellent batch-to-batch consistency
• Sustainable supply
• Animal-free production
See more details about Hi-Affi™ recombinant antibody benefits.
Download resources about recombinant antibody development and antibody engineering to boost your research.
Select a product category from the dropdown menu below to view related products.
CAT | Product Name | Application | Type |
---|---|---|---|
NABG-057 | Recombinant Anti-HIV-1 env VHH Single Domain Antibody | ELISA, IHC, FC, FuncS | Llama VHH |
There are currently no Customer reviews or questions for PABL-153. Click the button above to contact us or submit your feedback about this product.
To accurately reference this product in your publication, please use the following citation information:
(Creative Biolabs Cat# PABL-153, RRID: AB_3111630)
For Research Use Only. Not For Clinical Use.
For research use only. Not intended for any clinical use. No products from Creative Biolabs may be resold, modified for resale or used to manufacture commercial products without prior written approval from Creative Biolabs.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.